unlocking the future of physics today

Nusano’s breakthrough technologies are creating radiosiotope solutions for healthcare, industry and modern life

Nusano is a privately held physics company committed to bringing supply stability and innovation to the rapidly emerging and critically undersupplied medical radioisotopes market, and to serving industrial and commercial markets dependent on reliable access to high quality radioisotopes for their products and services. Driven by the company’s proprietary ion source, the Nusano production platform will generate radioisotopes in volumes and varieties exceeding other production methods. Nusano’s breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries.

Nusano

Leadership

Pioneered & driven by experts in nuclear medicine, radioisotope production & commercialization

Chris Lowe

Chief Executive Officer

Chris Lowe is an accomplished business leader with more than 30 years’ experience, the past 20 of which in C-suite and executive-level roles in healthcare and finance. Read more >>

HOWARD C. LEWIN, MD, FACC, FASNC

CO-FOUNDER & CHIEF PRODUCT DEVELOPMENT OFFICER

Dr. Howard Lewin is a globally recognized leader in nuclear cardiology imaging with training in Cardiology and Nuclear Medicine. Read more >>

GLENN B. ROSENTHAL, PH.D.

CO-FOUNDER & CHIEF TECHNOLOGY OFFICER

Dr. Glenn Rosenthal is an accomplished nuclear physicist, and former UCLA research physicist and lecturer.
Read more >>

Pushkar Bedekar

Chief Financial Officer

A 20-year veteran of the pharmaceuticals industry, Bedekar served as the CFO of U.S. Oncology for Novartis prior to joining Nusano. He oversees the company’s financial operations, including accounting, financial planning, tax, and treasury functions.

Kevin Haehl

Chief Product Officer

A 35-year veteran of pharma and biotech, Haehl drives value-creating opportunities for Nusano customers by ensuring excellence throughout the company’s product and supply chain operations.

Chris Ignace

SVP, Scientific Affairs

Ignace spent 13 years at Cardinal Health Nuclear and Precision Solutions in a variety of leadership roles. At Nusano, he applies his deep understanding of radiopharmaceutical development and regulatory processes to drive improved alignment and outcomes.

Rohan Jain

Chief Commercial Officer

Jain served as VP & Head of Novartis’ U.S. Radioligand Therapy Product Portfolio prior to joining Nusano. His Commercial team works with customers and prospects to enable current and future cancer therapeutics development.

Maggie Kruse

VP, People & Culture

Kruse is a HR executive whose career spans life sciences, financial services, technology, and manufacturing. She is growing Nusano’s innovative, science-driven culture to support current and future radioisotope applications.

Jzaneen Lalani

Chief Business Officer

Lalani has over 20 years’ experience managing life sciences companies across a wide variety of functional areas, including as a general counsel of public and privately-held companies. She oversees Nusano’s HR, legal, government affairs, and special projects functions.

Nusano

Board of Directors

Scott Holbrook

NUSANO BOARD CHAIR & GM-CSO, Pharmalogic

Scott has over twenty years’ experience in the field of molecular imaging and therapeutics.

DELL LOY HANSEN

FOUNDER & CEO, WASATCH GROUP

Dell Loy Hansen is the Founder and Chief Executive Officer of the Wasatch Group and is responsible for the overall management of its enterprises and affiliates.

JOHN DAHLSTROM

EVP - GENERAL COUNSEL, WASATCH PROPERTY MANAGEMENT

John is General Counsel of Wasatch Property Management, a fully integrated real estate development, construction, property management and guaranty capital company operating in six states.

Aaron Gerszewski

Managing Director, Wasatch Equity Partners

Aaron is managing partner at Wasatch Equity Partners, an investment firm with more than $4 billion assets under management.

Andy Harrison

CEO, Section 32

Andy is Managing Director and CEO of Section 32, a venture capital fund investing at the frontiers of technology.

Michael Pellini

Managing Partner, Section 32

Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology.

additional directors

company managers

Chris Lowe (CEO) and Howard Lewin (CPDO), also serve on the Board of Directors.